Asterias Biotherapeutics, Inc. Common Series A (AST): Downgrade News

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Key Facts Surrounding This News Item


  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) had a POWR Rating of F (Strong Sell) coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) was -4.02% below its 10-Day Moving Average coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) was -6.98% below its 20-Day Moving Average coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) was -5.80% below its 50-Day Moving Average coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) was -1.20% below its 100-Day Moving Average coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) was -18.58% below its 200-Day Moving Average coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) had returned -31.11% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.

More Info About Asterias Biotherapeutics, Inc. Common Series A (AST)


Asterias Biotherapeutics, Inc., a biotechnology company, focuses on the emerging field of regenerative medicines. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. The company was founded in 2012 and is based in Fremont, California. View our full Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) ticker page with ratings, news, and more.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Top Stories on StockNews.com

NYSE: NVS | Novartis AG  News, Ratings, and Charts

Sweet 16 Safe Stocks for this Volatile Market

The bull market is still in place, but appetite for risk is low. Novartis (NVS) is just one of 16 stocks with the right ingredients to excel in this volatile environment.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

Does 1 Equation Hold the Key for Stock Prices?

At first I thought it was outrageous to believe this 1 equation is only that mattered for stock prices. Then I saw it happen plain as day in February 2016. Now I believe it will happen again.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

Trump Delays Chinese Tariffs, is He Just Postponing the Inevitable?

In this featured article, Trump's postponement of Chinese tariffs is examined. Could the President be postponing the inevitable? Continue reading for more details.
: sndl | Sundial Growers Inc. News, Ratings, and Charts

Why are cannabis stock investors focusing on Sundial Growers (SNDL)?

Sundial growers are one of the most recent IPOs within the cannabis sector.
: CGC | Canopy Growth Corporation  News, Ratings, and Charts

Why did Canopy Growth's (CGC) stock plunge 14% today?

Canopy Growth Corp. (CGC) disappointed Wall Street yesterday with an earnings report that showed the worst bottom-line performance in the company’s history.

Read More Stories


More Asterias Biotherapeutics, Inc. Common Series A (AST) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AST News
Page generated in 2.1044 seconds.